One major difference between limb and extraocular muscles (EOM) is the presence of an enriched population of Pitx2-positive myogenic precursor cells in EOM compared to limb muscle. We hypothesize that retinoic acid regulates Pitx2 expression in EOM myogenic precursor cells and that its effects would differ in leg muscle. The two muscle groups expressed differential retinoic acid receptor (RAR) and retinoid X receptor (RXR) levels. RXR co-localized with the Pitx2-positive cells but not with those expressing Pax7. EOM-derived and LEG-derived EECD34 cells were treated with vehicle, retinoic acid, the RXR agonist bexarotene, the RAR inverse agonist BMS493, or the RXR antagonist UVI 3003. In vitro, fewer EOM-derived EECD34 cells expressed desmin and fused, while more LEG-derived cells expressed desmin and fused when treated with retinoic acid compared to vehicle. Both EOM and LEG-derived EECD34 cells exposed to retinoic acid showed a higher percentage of cells expressing Pitx2 compared to vehicle, supporting the hypothesis that retinoic acid plays a role in maintaining Pitx2 expression. We hypothesize that retinoic acid signaling aids in the maintenance of large numbers of undifferentiated myogenic precursor cells in the EOM, which would be required to maintain EOM normalcy throughout a lifetime of myonuclear turnover.
Introduction
The extraocular muscles (EOMs) are different from limb skeletal muscles developmentally, anatomically, physiologically, and biochemically [1] . One of the more unusual properties of uninjured adult EOMs is their continuous and significant levels of myonuclear remodeling throughout life due to the presence of chronically activated myogenic precursor cells [2] [3] [4] [5] . Recent studies using a reporter mouse for Pax7, a transcription factor expressed ubiquitously in satellite cells of skeletal muscle [6] , confirmed these earlier studies and showed a significant level of myonuclear turnover in the EOM [7, 8] . In contrast, uninjured adult limb skeletal muscles contain largely quiescent Pax7-positive myogenic precursor cells, and only after injury or in disease is there significant activation and proliferation of these cells [6, [9] [10] [11] [12] .
Other significant differences between EOMs and body muscle also exist. For example, distinct transcription factors are required for the early determination, development, and maintenance of EOMs compared to limb muscle [13, 14] . Specifically, the transcription factor Pitx2 is required for the development of EOMs, but is not required for the development of limb skeletal muscle [15] . Pitx2 expression is also maintained at high levels in adult EOMs compared to limb skeletal muscle [16, 17] , and this high level of Pitx2 expression is necessary to maintain characteristic properties of adult EOMs [16] [17] [18] .
Myogenic precursor cells within adult skeletal muscle are a diverse population, and this diversity is amplified in adult EOMs. Overall, the EOMs have an elevated density of different types of myogenic precursor cells compared to normal uninjured adult limb muscles [19, 20] . For example, there is an elevated density of Pax7-positive cells in EOMs compared to limb muscle [21] as well as an elevated population of EECD34 cells, identified using flow cytometry, which are positive for CD34 and negative for Sca1, CD45, and CD31 [19] . In a recent study, we described a significantly elevated population of myogenic precursor cells in EOMs that express Pitx2, which are essentially a non-overlapping population from those cells that express Pax7 [17, 20] . The roles played by these heterogeneous myogenic precursor cell populations in the function of the EOMs are unclear. Our recent study showed that high dose gamma irradiation (18 Gy) in a mouse model of muscular dystrophy differentially affected Pitx2 and Pax7 myogenic precursor cells and resulted in the transient appearance of dystrophic changescentrally located myonuclei -in the irradiated EOMs. This study suggests that these different precursor populations play different temporal and/or functional roles in EOM myofiber remodeling, repair, and regeneration [21] .
The factor(s) that maintain high levels of Pitx2 expression in adult EOMs are currently unknown. One candidate factor is retinoic acid, a vitamin A derivative. Retinoic acid regulates Pitx2 expression during ocular and craniofacial development [22, 23] . Without proper retinoic acid signaling during development, the EOMs do not form [24, 25] . Recent studies have implicated retinoic acid in globally regulating myogenic differentiation [26] . We tested the hypotheses that retinoic acid signaling differs in adult EOM and limb muscle myogenic precursor cells and that retinoic acid controls the maintenance of high levels of Pitx2 expression in adult EOMs and promotes proper function of the Pitx2-positive EOM myogenic precursor cells.
To test this hypothesis, we compared the expression of RARα, RARγ, RXRα, and RXRγ proteins in mouse EOMs and limb muscle. Next, the functional effects of modulating retinoic acid signaling were assessed in myogenic precursor cells in vitro isolated from mouse EOMs and limb muscle. Finally, to determine if retinoic acid acts to maintain Pitx2 expression in adult EOM myogenic precursor cells, the effect of retinoic acid signaling on expression of Pitx2 in EECD34 cells in vitro was assessed following addition of retinoic acid, RXR agonist, or inhibition of RXR function.
Results

EOMs express different levels of retinoic acid receptor and retinoid X receptor protein than limb skeletal muscle
Retinoic acid receptors (RARs) are nuclear receptors involved in retinoic acid signaling. The canonical retinoic acid signaling pathway involves the dimerization of RAR with retinoid X receptors (RXR) [27] . The RAR-RXR dimers then bind to retinoic acid response elements and stimulate the transcription of retinoic acid responsive genes. However, recent data show that these nuclear receptors can be differentially regulated and can each function in an independent manner in cells [28] [29] [30] [31] . To determine if retinoic acid receptors were differentially expressed in EOMs compared to limb muscle, we used western blots to assess the amount of retinoic acid receptor alpha (RARα) and gamma (RARγ) expressed in EOM and LEG whole tissue lysates. RARα protein levels were significantly higher in LEG whole tissue lysates compared to EOM whole tissue lysates, with LEG samples expressing 4-fold more RARα than the EOMs (Fig. 1A, B) . However RARγ levels were not statistically significantly different in LEG whole tissue lysates compared to EOM whole tissue lysates (Fig. 1C, D) . In contrast, retinoid X receptor alpha (RXRα) and gamma (RXRγ) protein levels were significantly higher in EOM whole tissue lysates, with EOM expressing over almost 91.7% more RXRα than LEG whole tissue lysates (Fig. 1E, F ) and 106% more RXRγ (Fig. 1G, H ).
RXRα co-expresses with Pitx2 but not Pax7
The potential myogenic identity of the precursor cells expressing RXRα was examined in tissue sections of EOMs from adult mice. Nuclear expression of RXRα was evident in sections from EOM (Figs. 2 and 3), but was only sparsely found in sections of leg muscle (not shown). The RXRα positive nuclei were seen to co-express Pitx2 (Fig. 2) . Using a Pax7 reporter mouse [8] , the Pax7-expressing satellite cells did not co-express RXRα (Fig. 3 ). This suggested a strong interrelationship between RXRα and Pitx2 expression. Note also the RXRα-positive myonuclei in addition to the RXRα-positive cells outside of the sarcolemma (Fig. 3D ).
EOM-derived EECD34 cells maintain Pitx2 expression in vitro
-/CD31 -) are a subpopulation of myogenic precursor cells, the majority of which are positive for Pitx2 [17, 19] . To determine if EECD34 cells derived from the EOMs retained their Pitx2 expression in vitro, cells were immunostained one, two, three, and four days after plating in proliferation media. At one and two days after the EECD34 cells were plated in proliferation media, essentially 100% of the cells were Pitx2 positive (Fig. 4A, B, D) . In these cultures, dividing cells were often present (Fig. 4A) , and both daughter cells retained their Pitx2 expression at these time points. By 72 h in vitro, 92.3 ± 3.6% of the cells were still Pitx2 positive (Fig. 4C, D) , and the vast majority of dividing cells were still both Pitx2 positive (not shown). By 96 h in proliferation medium, 95.0 ± 0.6% % of the cells were Pitx2-positive. This demonstrates that at the time of the proliferation assay, the EECD34 cells retained their Pitx2 expression.
EECD34 cell proliferation is unchanged by additional retinoic acid or reduced retinoic acid signaling
Knockdown of Pitx2 expression in EECD34 cells in vitro significantly reduced their proliferation rate [17] . Given the potential role for retinoic acid to regulate Pitx2 expression in adulthood, as it does during development, and the significant role played by Pitx2 in regulating the proliferation rates of EECD34 cells, EECD34 cell proliferation rates were assessed following the addition of retinoic acid and retinoic acid signaling modulators. The effect of retinoic acid, the pan-RAR inverse agonist BMS493, and the RXR antagonist UVI 3003 on the proliferation rate of EECD34 cells in vitro was determined by calculating the percentage of cells that incorporated the thymidine analog EdU following treatment. Addition of retinoic acid, BMS493, or UVI 3003 did not change the proliferation rate of EOM-derived or LEG-derived EECD34 cells compared to control cells ( Fig. 5A-E) . However, in EOM-derived EECD34 cells there was a significant difference in proliferation rates between cells treated with the RAR inverse agonist compared to those treated with retinoic acid, with RAR inverse agonist treated cells having 29.7% more EdU-positive cells than retinoic acid treated cells (Fig. 5E) . Consistent with previous results [17] , there were significantly more EdU-positive EOM-derived EECD34 cells compared to LEG-derived EECD34 cells under all conditions except the retinoic acid treatment, with proliferation rates 44.9% higher in control cultures, 30.3% higher in the presence of retinoic acid, 72.1% higher in the presence of the RAR inverse agonist, and 52.5% higher in the presence of the RXR antagonist (Fig. 5E ).
EECD34 cell fusion and desmin expression is changed after modulation of retinoic acid signaling
Knockdown of Pitx2 expression in EECD34 cells in vitro significantly reduced their fusion index [17] . Given the potential role for retinoic acid to regulate Pitx2 expression in adulthood as it does during development, and the role of Pitx2 in regulating fusion of EECD34 cells, we investigated if the addition of retinoic acid, BMS493, or UVI 3003 altered the fusion and desmin expression of EECD34 cells in vitro. Following 72 h incubation in fusion media containing vehicle, retinoic acid, BMS493, or UVI 3003, the cells were immunostained for desmin, followed by hematoxylin staining (Fig. 6) , counted, and the cell fusion index and percent of differentiated cells were calculated. Under all conditions the LEG-derived EECD34 cells had a significantly greater fusion index compared to EOM-derived EECD34 cells (Fig. 7A) For the EOM-derived EECD34 cells, the cells treated with retinoic acid showed a significant 43.4% lower fusion index compared to vehicle treated control cells (Fig. 7A) . Treatment of the EOM-derived EECD34 cells with the RAR inverse agonist or RXR antagonist resulted in a similar fusion index compared to the vehicle-treated control cells. In addition, the fusion rate of the EOM-derived EECD34 cells treated with either the RAR inverse agonist or RXR antagonist were significantly greater than the cells treated with retinoic acid (Fig. 7A) . In contrast, treatment of the LEG-derived EECD34 cells with retinoic acid resulted in a 31% higher fusion index compared to the vehicle treated cells. There was no significant difference in the fusion index after treatment of the LEG-derived EECD34 cells with the two receptor inhibitors compared to control. However, there was a significant 41.2% difference in the fusion index between the LEG-derived EECD34 cells treated with retinoic acid and those treated with BMS493 (Fig. 7A) . For the LEG-derived EECD34 cells, there was no significant difference in the fusion index after RXR inhibition compared to any of the other treatments.
Mononuclear cells that were positive for desmin indicated that they had differentiated but did not fuse with other cells. All the LEG-derived EECD34 cultures had a higher percentage of desmin-positive mononuclear cells than the EOM-derived EECD34 cells under similar culture conditions (Fig. 7B ). There were no significant differences in the percentage of desmin-positive mononuclear cells in the EOM-derived EECD34 cells treated with vehicle, retinoic acid, BMS493, or UVI 3003 (Fig. 7B ). When the cultures of the LEG-derived EECD34 cells were examined, there were significantly fewer mononuclear desmin-positive cells after retinoic acid treatment compared to the control cultures, where 17.5 ± 7.7% were desmin-positive in retinoic acid treated cells compared to 36.0 ± 2.6% in vehicle treated control cells (Fig. 7B ). This represented a 69.3% difference. There were also significantly more desmin-positive mononuclear cells after treatment of the LEG-derived EECD34 cells with the RAR inverse agonist compared to those treated with the retinoic acid, representing a 79% difference. There was no significant difference in the number of desmin positive LEG-derived EECD34 cells after RXR inhibition compared to any of the other treatments.
Desmin-negative cells were also analyzed, as these cells suggest maintenance of an undifferentiated state (Fig. 7C ). For each condition, 
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there were significantly greater numbers of desmin-negative cells for the EOM-derived EECD34 cells than for the LEG-derived EECD34 cells, with a 154.4% difference for the vehicle treated cells, an 165.5% difference for the retinoic acid treated cells, a 133.5% difference for the RAR inverse agonist treated cells, and a 136% difference for the cells treated with RXR antagonist (Fig. 7C ). In the EOM-derived EECD34 cells treated with retinoic acid, there were significantly more desminnegative cells than in vehicle treated control cultures, 75.26 ± 3% compared to 57.15 ± 4.6% for the control cultures, a difference of 31.7% (Fig. 7C ). While they were not significantly different from the control cultures, both the RAR inverse agonist and RXR antagonist resulted in significantly fewer desmin-negative cells in the EOM-derived EECD34 cells compared to those treated with retinoic acid, at 54.8 ± 3.1% and 56.1 ± 5.5% respectively, representing differences of approximately 30%. There were no significant differences in percent of nuclei that were desmin-negative in the LEG-derived EECD34 cells between any of the treatment conditions. The mean length of the myotubes that formed in vitro was 
determined for all treatment conditions. There were no significant differences in the mean length of myotubes in any of the 4 conditions from the EOM-derived EECD34 cells (Fig. 8) . However, retinoic acid treatment of the LEG-derived EECD34 cells resulted in significantly longer myotubes in vitro, 438.2 ± 59.2 µm in the retinoic acid treated cells compared to 256.9 ± 13.8 µm in control cells (Fig. 8 ). This was a 52.1% difference in length between retinoic acid treated cells and control cells. Myotubes from retinoic acid treated LEG-derived EECD34 cells were also significantly longer than myotubes from LEG-derived EECD34 cells treated with either RAR inverse agonist or RXR antagonist. The mean myotube length in the retinoic acid treated cultures was 63.9% and 40% longer than in the cultures treated with RAR inverse agonist and RXR antagonist, respectively.
Retinoic acid modulates Pitx2 expression in EOM-derived EECD34 cells in vitro
If retinoic acid signaling is important for the maintenance of Pitx2 expression, then altering retinoic acid signaling should also alter the expression of Pitx2 in the myogenic precursor cells. Pitx2 expression was assessed in vitro 24 h after the addition of vehicle, retinoic acid, the RAR inverse agonist BMS493, the RXR agonist bexarotene, or the RXR antagonist UVI3003 to EOM and LEG-derived EECD34 cells in a low serum media. In the cultures from EOM-derived EECD34 cells treated with retinoic acid, the percent of Pitx2-positive cells was significantly higher compared to vehicle-treated control cells, 80 ± 6.08% compared to 21.75 ± 2.8%, a 115% difference (Fig. 9A, B, E) . Similarly, the cultures treated with the RXR agonist were 81.16 ± 4.3% Pitx2-positive, a 116% difference from vehicle treated EOM-derived EECD34 cells (Fig. 9A, C, E) . Both the retinoic acid and RXR agonist treated cultures had significantly more Pitx2-positive cells than the cultures treated with the RXR antagonist UVI3003, where only 34.5 ± 10.8% were Pitx2-positive, a 79.5% and 81% difference, respectively, from the RXR antagonist treated cells (Fig. 9B-E) . The largest difference was seen in the cultures treated with the RAR inverse agonist, which had significantly fewer Pitx2-positive cells than those cultures treated with retinoic acid, RXR agonist, and RXR antagonist, with differences of 171.9%, 172.2%, and 140.3% respectively.
In the EECD34 cultures derived from LEG muscle, there was a significant difference between the numbers of cells positive for Pitx2 after retinoic acid treatment, at 61.2 ± 3.5%, compared to vehicle treated controls, at 32.9 ± 2.1%, and represents a 61.2% difference (Fig. 9F ). There were also significantly more cells expressing Pitx2 in the RXR agonist treated cultures, at 58.66 ± 9.15% relative to vehicle treated controls, a 52.3% difference. There were 61.9% significantly fewer cells expressing Pitx2 in the RXR antagonist treated cultures, at 32.3 ± 5.6%, compared to the cultures treated with retinoic acid, There were no differences in the percent of cells expressing Pitx2 after RXR antagonist treatment compared to control cultures.
In summary, retinoic acid significantly increased the percent of cells that expressed Pitx2 in the EECD34 cells derived from EOM and LEG. This supports the hypothesis that Pitx2 expression levels may be, at least in part, controlled by retinoic acid levels at these time points.
Discussion
Retinoic acid signaling was shown in previous studies to be critical for the up-regulation of Pitx2 expression, and the upregulation of the transcription factor Pitx2 was critical for the formation of the EOMs [14, 25] . If either retinoic acid signaling or Pitx2 expression was inhibited, no EOMs developed. The expression of Pitx2 was found to be down-regulated in skeletal muscle after early development of limb skeletal muscles [32] , but continued to be expressed at high levels in the extraocular muscles throughout life [16] [17] [18] Pitx2 was expressed in a large number of myonuclei in mature EOMs [16, 18] , as well as in myogenic precursor cells found both in the traditional satellite cell location and in the interstitial connective tissue [17] . Thus, we hypothesized that the continued expression of Pitx2 in adult EOMs was due to maintenance of retinoic acid signaling.
Retinoic acid receptor expression
The EOMs expressed lower levels of RARα compared to limb skeletal muscle, similar levels of RARγ, and expressed high relative levels of RXRα and RXRγ. While the canonical signaling of retinoic acid is through RAR:RXR dimers, a number of studies showed that there was differential regulation of RAR and RXR during proliferation and differentiation [28, 30] . In addition, RXR-mediated signaling was shown to enhance specification of the muscle specific lineage in an RAR-independent manner [31] . Thus, while both receptors were present, their different expression levels in EOMs and limb muscles suggest that there is functional specificity in the roles they play in the maintenance of these muscles in mature animals.
Retinoic acid treatment and proliferation
At the commencement of the proliferation assay, the vast majority of the EECD34 cells in vitro were Pitx2-positive. Addition of retinoic acid, RAR inverse agonist, or RXR antagonist to EOM-or LEG-derived EECD34 cells in vitro did not alter rates of proliferation under any of the treatment conditions compared to the vehicle treated control cultures. For the EOM-derived EECD34 cells, only treatment with the RAR inverse agonist had a significant effect on proliferation rate compared to that of the retinoic acid treated cells. The cells grown under the control conditions were in proliferation medium, which contains 20% serum; normal serum contains high levels of retinoic acid, normally at a concentration of 4-5 ng/ml [33, 34] . One hypothesis for the lack of effect of retinoic acid treatment on proliferation rates in the EECD34 cells in vitro is that the high serum levels of the proliferation medium already contained significant levels of retinoic acid. This suggests that it may be necessary to remove it from the culture medium to see an effect on proliferation in vitro. Because the RAR receptor is constitutively active [35] , the inverse agonist was required in order to see a significant effect on proliferation rates in the EOM-derived EECD34 cells compared to retinoic acid. This is supported by the reduced numbers of cells that expressed Pitx2 within one day of switching from the proliferation medium, where almost all cells were Pitx2 positive, to approximately 20% expressing Pitx2 when the serum levels, and consequently the retinoic acid levels, in the medium were reduced.
Retinoic acid signaling and differentiation
The effect of retinoic acid on fusion into myotubes, defined as cells that contained at least two nuclei, was noticeably different in the EOMderived EECD34 cells compared to the LEG-derived EECD34 cells. In the LEG-derived EECD34 cells, there were significantly fewer mononucleated desmin positive cells, but overall 91.5% of the retinoic acid treated LEG-derived EECD34 cells expressed desmin. This demonstrated that for the LEG-derived EECD34 cells, retinoic acid functioned to induce differentiation, promoting the expression of desmin and fusion into myotubes compared to the vehicle-treated control cells. However, due to the presence of retinoic acid in the culture medium, the differences between cells treated with retinoic acid and the RAR inverse agonist provide the greatest significant insight into the potential role of retinoic acid signaling in these LEG-derived cells. While the addition of the RAR inverse agonist decreased the level of fusion of the LEG-derived EECD34 cells in vitro by one third, it also resulted in a greater number of desmin-positive mononuclear cells. This suggests a specific role for retinoic acid in promoting fusion of these LEG-derived cells in vitro. These results correlate with the high levels of RAR receptor expressed by these cells. There are a large number of studies in vivo and in vitro showing the enhancement of muscle precursor cell differentiation by retinoic acid [26, 36, 37] . In fact, recent work demonstrated efficacy of using RAR agonists to promote repair after skeletal muscle injury in vivo [38] . The lack of effect of the RXR antagonist was expected in the LEGderived EECD34 cell cultures in light of their lower levels of RXR receptor expression.
A significantly different picture was seen after addition of retinoic acid to EOM-derived EECD34 cells, where fusion was inhibited by 50% compared to the control cultures. In contrast to the high level of fusion 
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in the LEG muscle-derived cells, 75.3 ± 3% of the EOM-derived EECD34 cells remained desmin-negative in the low serum fusion medium containing retinoic acid compared to 7.1 ± 3% from LEG-derived EECD34 cells. Both the RAR inverse agonist and the RXR antagonist treatments showed similar results to controls relative to fusion index and desmin expression patterns. Comparatively speaking, however, in all the cultures of EOM-derived EECD34 cells, approximately 60% remained desmin-negative. The desmin-negative cells represented a small minority of the LEG-derived EECD34 cells, which averaged between 5% and 10%. Others have shown that retinoic acid treatment of embryonic stem cells promotes the expansion of the premyogenic progenitor population [37] . A recent study using primary human myoblasts also showed that retinoic acid impaired skeletal muscle differentiation [39] . However, as studies in other muscle precursor cell types had the reverse effect, pushing the cells toward expression of MyoD and myogenin [26, 36, 40] , it would appear that culture conditions, type of cells isolated, and whether the cells are primary or cell lines, affect the downstream changes induced by modulation of retinoic acid signaling. In EOM-derived EECD34 cells cultured directly ex vivo, the effect of retinoic acid treatment was to decrease fusion. This is interesting in light of their dependence for embryological development, including both size and location, on retinoic acid produced by neural crest cells early in development [24, 25] . Further, this signaling was linked to RXR specifically [22] . The current studies show that there is a specific population of muscle stem cells, enriched in the EOM, that have a significantly different response to retinoic acid signaling compared to the "same" cells derived from limb skeletal muscles. These data implicate retinoic acid in playing a potential role in preventing fusion of these cells into normal adult EOM, the effect we hypothesize may be to promote their longer-term retention, which is needed considering the significant level of remodeling that occurs throughout life in mature EOM [2, 5, 7, 8] .
Levels of Pitx2: modulation by retinoic acid signaling
The ability of retinoic acid and the RXR agonist bexarotene to significantly increase the number of Pitx2-expressing EECD34 cells strongly supports the role of this signaling pathway in the normal maintenance of Pitx2 expression in the adult EOM. Retinoic acid is known to be a potent enhancer of skeletal muscle myogenesis of various myogenic cell lines in vitro [36, 40] . It was shown previously that retinoic acid acts in opposite ways on distinct populations of myogenic precursor cells [41] . However, none of the various treatments resulted in all of the cells responding in a similar manner. The EECD34 cells are not a "pure" population [17] , and this is probably reflected in the differential effectiveness of the agonists and antagonists used in this study to modulate Pitx2 expression for both the EOM-and LEG-derived EECD34 cells. In particular, RXR plays a number of roles outside of retinoic acid signaling, including signaling with the thyroid hormone receptor, peroxisome proliferator-activated receptor (PPAR) and others [42, 43] . In addition, while the percent of serum was greatly reduced in low serum fusion medium compared to proliferation medium, retinoic acid was still present within the fusion medium. If defined medium without serum was used, the effects for all treatments might have been more visible in the assays used in this study.
Summary
In conclusion, there are different levels of retinoic acid signaling receptor proteins in limb compared to extraocular muscles. The treatments with retinoic acid, an RAR inverse agonist, or an RXR antagonist resulted in significantly different responses. In the cultures treated with retinoic acid, the LEG-derived EECD34 cells responded with an increase in cells expressing desmin and increased fusion compared to control cultures, while the EOM-derived EECD34 cells responded with significantly more cells negative for desmin as well as decreased fusion.
This suggests that the EECD34 cells used in these cultures are heterogeneous, and that the fate of these cells in the milieu of the EOM is distinctly different than these cells when in the milieu of leg muscles. The identity of these other factors is unknown. In the EOM, where there is a 10-fold increased density of Pitx2-positive myogenic precursor cells compared to leg muscle [27] , we hypothesize that retinoic acid signaling may play a role in maintaining large numbers of Pitx2-expressing cells in the EOM by inhibiting their fusion into myofibers, allowing their extensive and life-long myonuclear turnover rates. Further studies are needed to determine if this occurs in vivo.
Methods
Animals
All experiments adhered to NIH guidelines for the use of animals in research and were approved by the Institutional Animal Care and Usage Committee at the University of Minnesota. C57BL/6 mice (Envigo, Madison, WI) were housed and maintained by Research Animal Resources at the University of Minnesota. All adult mice were sacrificed by CO 2 asphyxiation.
Western blotting
For whole tissue lysates, EOMs and tibialis anterior (LEG) were removed from C57BL/6 mice and immediately placed into ice-cold Dulbecco's minimal essential medium (DMEM) or snap-frozen in liquid nitrogen. Each EOM sample contained all eight rectus muscles pooled from three mice, and each LEG sample contained the right tibialis anterior muscle pooled from three mice. Muscles placed in DMEM were removed from media, weighed, and placed in a glass homogenizer on ice containing 100 ml of 1X cell lysis buffer (Cell Signaling, Danvers, MA) with Complete® Protease Inhibitor Cocktail (Roche, Indianapolis, IN) per 10 mg of muscle. To process the frozen samples, muscles were removed and pulverized to a powder in glass homogenizer tubes on dry ice. Samples were then allowed to thaw on ice and homogenized in 300uL or 1800uL RIPA buffer (Sigma, St. Louis, MO) with Complete® Protease Inhibitor Cocktail (Roche) for EOM and LEG respectively. All homogenized samples were centrifuged at 11,000 g for 20 min at 4°C. Supernatants were transferred to ice-cold tubes and stored at − 30°C. Protein concentrations were determined by the bicinchoninic acid (BCA) protein assay (Thermo Scientific; Waltham, MA). 8-33 µg of protein was separated on Any kD mini-PROTEAN TGX precast gels (BioRad, Hercules, CA) and transferred to nitrocellulose. Membranes were dried for 1 h after transfer, then stained with the REVERT™ Total Protein Stain Kit (LI-COR Biosciences, Lincoln, NE) and imaged with an Odyssey Infrared Imaging System (LI-COR Biosciences) before the stain was reversed. Membranes were blocked in Odyssey blocking solution (LI-COR Biosciences) for 1 h at room temperature, then incubated with one of the following primary antibodies: retinoic acid receptor alpha (1:500, RARα, abcam, Cambridge, MA), retinoic acid receptor gamma (1:1000; RARγ, abcam), retinoid X receptor alpha (1:1000; RXRα, abcam), or retinoid X receptor gamma (1:100; RXRγ, abcam) overnight at 4°C. The next day membranes were washed in Tris-buffered saline and Tween 20 (TBST) (1X TBS, 0.1% Tween 20) and incubated in goat anti-rabbit-IR800CW (1:20,000; LI-COR Biosciences) for 1 h at room temperature. After rinsing in TBST, the membranes were imaged with the Odyssey Infrared Imaging System. Densitometry values were obtained using Odyssey instrument software.
4.3. Immunohistochemistry 4.3.1. Identification of RXR expression in tissue sections. Cryostat sections through adult C57BL/6 mouse EOMs were immunostained for the expression of RXR and its co-expression with specific markers of myogenic precursor cells. Sections were fixed in 4% paraformaldehyde (Affymetrix, San Diego, CA), rinsed in phosphate buffered saline (PBS), blocked in 20% normal serum, followed by incubation in primary antibody to RXRα (1:100, abcam, Cambridge, MA) in antibody buffer containing PBS and 0.1% Triton X-100 overnight at 4°C, rinsed in PBS, blocked in 20% normal serum, followed by incubation in goat anti-rabbit Alexa Fluor 488 (1:1000, Jackson ImmunoResearch, West Grove, PA) in antibody buffer. The sections were then incubated in Fab fragments diluted in antibody buffer overnight at 4 o C. The following day, the sections were rinsed in PBS, blocked in 20% normal serum, and incubated with an antibody to Pitx2 in antibody buffer at room temperature for 1 h (1:1500; Capra Science, Ängelholm, Sweden). After incubation, the tissue was rinsed in PBS, blocked in 20% normal serum, followed by incubation in goat antirabbit Rhodamine Red antibody (1:1000; Jackson ImmunoResearch) in antibody buffer, rinsed in PBS. The sections were next treated with antidystrophin (1:200, Sigma), rinsed with PBS, followed by incubation with goat anti-rabbit IgG-conjugated to dylight 405 (1:100, Jackson Labs.), and mounted with Vectashield (Vector Laboratories, Burlingame, CA). A second series used sections from the Pax7-tdTomato reporter mouse (Pax7 Cre ; R26R tdTomato ). These were fixed in 4% paraformaldehyde prior to cryosectioning. These sections were then rinsed in PBS, blocked in 20% normal serum, incubated in primary antibody to RXRα, and processed similarly to those sections immunostained for Pitx2. The sections were next treated with antidystrophin (1:200, Sigma), rinsed with PBS, followed by incubation with goat anti-rabbit IgG-conjugated to dylight 405 (1:100, Jackson Labs.), and mounted with Vectashield (Vector Laboratories). 4.6. EdU (5-ethynyl-2′-deoxyuridine) proliferation assay Proliferation rates of treated cells were determined at the end of the 24-h treatment using the Click-iT® EdU kit (Invitrogen, Carlsbad, CA). Cells were incubated with 20 μM EdU (a thymidine analog) in proliferation media for 1 h. Immediately following the 1-h incubation, cells were fixed and labeled with Oregon Green 488 according to the manufacturer's instructions. Cells were mounted in Vectashield Mounting Media with DAPI (Vector Laboratories) and examined by fluorescence microscopy at 20× magnification. A minimum of 200 nuclei from at least 4 fields were counted for each independent experiment. A minimum of three independent replicates were analyzed for the LEG samples, and nine independent replicates were analyzed for the EOM samples.
Fusion assay
At the end of the 72-h treatment the cells were stained for desmin to determine the amount of cell fusion. Cells were rinsed with PBS, fixed with 4% paraformaldehyde for 10 min, rinsed, blocked with 10% horse serum in antibody buffer for 30 min, blocked using the Avidin/Biotin blocking kit (Vector Laboratories), and incubated for one hour with an antibody to desmin (Dako, 1:500) in antibody buffer. Desmin was detected using the Vectastain ABC kit (Vector Laboratories) and diaminobenzidine. Cells were counterstained with hematoxylin. The fusion index was calculated as the number of nuclei present in myotubes defined as containing two or more nuclei divided by the total number of nuclei. Percent desmin-positive and percent desmin-negative mononuclear cells were calculated as the number of individual nuclei with or without desmin immunostaining, respectively, divided by the total number of nuclei. Cells were visualized at 20X magnification. A minimum of 200 nuclei from at least 4 fields were counted for each independent experiment. A minimum of three to five independent replicates were analyzed for the LEG samples, and nine to twelve independent replicates were analyzed for the EOM samples. For myotube length, 36 consecutive 20X images were stitched together into a 6 × 6 square using Adobe Photoshop (Adobe Systems, San Jose, California), and full length myotubes were measured using the Bioquant Image Analysis System (Bioquant, Nashville, TN). Four to twelve independent replicates were measured, means for each replicate were averaged, and the averages were used to determine significant differences between the treatments.
Statistical analysis and data availability
Data are reported as means ± SEM. Data were analyzed with a twoway analysis of variance (ANOVA) followed by a post-hoc Tukey's multiple comparison test with aid of Prism software (Graphpad). Statistical significance was defined as P < 0.05.
All data and associated protocols will be made available to readers on request.
